European Heart Journal
Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction
Experiments in animalsInterventions
Papers by Natalie Gehred
3 results
- AHA Scientific Sessions 2025 Abstract
GLP-1 Receptor Agonist Semaglutide Improves Hepatic Metabolism and Reverses Hepatic Steatosis Independent of Weight Loss in Cardiometabolic HFpEF
Experiments in animalsInterventions - AHA Scientific Sessions 2025 Abstract
Low-Dose GLP-1 Receptor Agonist Therapy Exerts Anti-Fibrotic Effects Across Multiple Organs in Cardiometabolic HFpEF
Experiments in animalsInterventions